Abstract
To the Editor: Both intravenous antibody-drug conjugates and oral tyrosine kinase inhibitors targeting receptor tyrosine-protein kinase erbB-2 (ERBB2 ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
